No.,Title,Link
1,"Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0235-1
2,Adherence to antiretroviral therapy and the associated factors among people living with HIV/AIDS in Northern Peru: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0238-y
3,Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA),http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0236-0
4,"Impact of HIV testing and treatment services on risky sexual behaviour in the uMgungundlovu District, KwaZulu-Natal, South Africa: a cross-sectional study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0237-z
5,"Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country?",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0234-2
6,Differences in HIV testing and receipt of results between adolescent and non-adolescent women in Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0233-3
7,Social barriers in accessing care by clients who returned to HIV care after transient loss to follow-up,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0231-5
8,Primary cutaneous actinomycosis: a diagnosis consideration in people living with HIV/AIDS,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0232-4
9,Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0230-6
10,Spatiotemporal analysis and epidemiological characterization of the human immunodeficiency virus (HIV) in Libya within a twenty five year  period: 1993–2017,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0228-0
11,"HIV risk, risk perception and uptake of HIV testing and counseling among youth men who have sex with men attending a gay sauna",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0229-z
12,Tenofovir-associated kidney disease in Africans: a systematic review,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0227-1
13,Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0226-2
14,Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0225-3
15,Development of a neurocognitive test battery for HIV-associated neurocognitive disorder (HAND) screening: suggested solutions for resource-limited clinical settings,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0224-4
16,Feasibility and yield of HIV screening among adult trauma patients presenting to an urban emergency department of a tertiary referral hospital in Tanzania,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0223-5
17,Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0222-6
18,HIV late presentation and advanced HIV disease among patients with newly diagnosed HIV/AIDS in Southwestern China: a large-scale cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0221-7
19,High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0220-8
20,Moderate prevalence of HIV-1 transmitted drug resistance mutations in southern Brazil,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0219-1
21,First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0218-2
22,What causes non-adherence among some individuals on long term antiretroviral therapy? Experiences of individuals with poor viral suppression in Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0214-y
23,HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0217-3
24,Looking at the positives: proactive management of STIs in people with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0216-9
25,Two cases of relapsed HIV-associated visceral leishmaniasis successfully treated with combination therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0215-x
26,Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal?,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0213-z
27,Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0212-0
28,"Cost and cost-effectiveness of voluntary medical male circumcision in street-connected youth: findings from an education-based pilot intervention in Eldoret, Kenya",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0207-x
29,Long-term virological outcome in children receiving first-line antiretroviral therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0208-9
30,Ageing in patients with chronic HIV infection: impact of hypercoagulation,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0211-1
31,Processes and dynamics of linkage to care from mobile/outreach and facility-based HIV testing models in hard-to-reach settings in rural Tanzania. Qualitative findings of a mixed methods study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0209-8
32,Factors associated with viral non-suppression among adolescents living with HIV in Cambodia: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0205-z
33,Frailty in people living with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0210-2
34,Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0206-y
35,A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0204-0
36,Non-AIDS defining cancer (NADC) among HIV-infected patients at an oncology tertiary-care center in Mexico,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0202-2
37,Risky sexual behavior among patients on long-term antiretroviral therapy: a prospective cohort study in urban and rural Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0203-1
38,"Increases in condomless chemsex associated with HIV acquisition in MSM but not heterosexuals attending a HIV testing center in Antwerp, Belgium",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0201-3
39,CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0200-4
40,"Linking gender, extramarital affairs, and HIV: a mixed methods study on contextual determinants of extramarital affairs in rural Tanzania",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0199-6
41,Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0198-7
42,"Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0196-9
43,Multivariate analysis of covariates of adherence among HIV-positive mothers with low viral suppression,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0197-8
44,Social-support needs among adolescents living with HIV in transition from pediatric to adult care in Cambodia: findings from a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0195-x
45,"Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0194-y
46,Non-AIDS complexity amongst patients living with HIV in Sydney: risk factors and health outcomes,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0193-z
47,Prognostic indicators in the World Health Organization’s algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0192-0
48,Quality improvement as a framework for behavior change interventions in HIV-predisposed communities: a case of adolescent girls and young women in northern Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0190-2
49,Prevalence of lower limb deep venous thrombosis among adult HIV positive patients attending an outpatient clinic at Mulago Hospital,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0191-1
50,Geographic patterns of poor HIV/AIDS care continuum in District of Columbia,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0189-8
51,"Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0235-1
52,Adherence to antiretroviral therapy and the associated factors among people living with HIV/AIDS in Northern Peru: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0238-y
53,Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA),http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0236-0
54,"Impact of HIV testing and treatment services on risky sexual behaviour in the uMgungundlovu District, KwaZulu-Natal, South Africa: a cross-sectional study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0237-z
55,"Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country?",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0234-2
56,Differences in HIV testing and receipt of results between adolescent and non-adolescent women in Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0233-3
57,Social barriers in accessing care by clients who returned to HIV care after transient loss to follow-up,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0231-5
58,Primary cutaneous actinomycosis: a diagnosis consideration in people living with HIV/AIDS,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0232-4
59,Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0230-6
60,Spatiotemporal analysis and epidemiological characterization of the human immunodeficiency virus (HIV) in Libya within a twenty five year  period: 1993–2017,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0228-0
61,"HIV risk, risk perception and uptake of HIV testing and counseling among youth men who have sex with men attending a gay sauna",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0229-z
62,Tenofovir-associated kidney disease in Africans: a systematic review,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0227-1
63,Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0226-2
64,Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0225-3
65,Development of a neurocognitive test battery for HIV-associated neurocognitive disorder (HAND) screening: suggested solutions for resource-limited clinical settings,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0224-4
66,Feasibility and yield of HIV screening among adult trauma patients presenting to an urban emergency department of a tertiary referral hospital in Tanzania,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0223-5
67,Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0222-6
68,HIV late presentation and advanced HIV disease among patients with newly diagnosed HIV/AIDS in Southwestern China: a large-scale cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0221-7
69,High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0220-8
70,Moderate prevalence of HIV-1 transmitted drug resistance mutations in southern Brazil,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0219-1
71,First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0218-2
72,What causes non-adherence among some individuals on long term antiretroviral therapy? Experiences of individuals with poor viral suppression in Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0214-y
73,HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-019-0217-3
74,Looking at the positives: proactive management of STIs in people with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0216-9
75,Two cases of relapsed HIV-associated visceral leishmaniasis successfully treated with combination therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0215-x
76,Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal?,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0213-z
77,Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0212-0
78,"Cost and cost-effectiveness of voluntary medical male circumcision in street-connected youth: findings from an education-based pilot intervention in Eldoret, Kenya",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0207-x
79,Long-term virological outcome in children receiving first-line antiretroviral therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0208-9
80,Ageing in patients with chronic HIV infection: impact of hypercoagulation,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0211-1
81,Processes and dynamics of linkage to care from mobile/outreach and facility-based HIV testing models in hard-to-reach settings in rural Tanzania. Qualitative findings of a mixed methods study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0209-8
82,Factors associated with viral non-suppression among adolescents living with HIV in Cambodia: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0205-z
83,Frailty in people living with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0210-2
84,Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0206-y
85,A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0204-0
86,Non-AIDS defining cancer (NADC) among HIV-infected patients at an oncology tertiary-care center in Mexico,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0202-2
87,Risky sexual behavior among patients on long-term antiretroviral therapy: a prospective cohort study in urban and rural Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0203-1
88,"Increases in condomless chemsex associated with HIV acquisition in MSM but not heterosexuals attending a HIV testing center in Antwerp, Belgium",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0201-3
89,CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0200-4
90,"Linking gender, extramarital affairs, and HIV: a mixed methods study on contextual determinants of extramarital affairs in rural Tanzania",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0199-6
91,Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0198-7
92,"Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0196-9
93,Multivariate analysis of covariates of adherence among HIV-positive mothers with low viral suppression,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0197-8
94,Social-support needs among adolescents living with HIV in transition from pediatric to adult care in Cambodia: findings from a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0195-x
95,"Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0194-y
96,Non-AIDS complexity amongst patients living with HIV in Sydney: risk factors and health outcomes,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0193-z
97,Prognostic indicators in the World Health Organization’s algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0192-0
98,Quality improvement as a framework for behavior change interventions in HIV-predisposed communities: a case of adolescent girls and young women in northern Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0190-2
99,Prevalence of lower limb deep venous thrombosis among adult HIV positive patients attending an outpatient clinic at Mulago Hospital,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0191-1
100,Geographic patterns of poor HIV/AIDS care continuum in District of Columbia,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0189-8
101,Mental health service utilization is associated with retention in care among persons living with HIV at a university-affiliated HIV clinic,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-018-0188-9
102,A cluster randomized controlled trial of lay health worker support for prevention of mother to child transmission of HIV (PMTCT) in South Africa,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0187-2
103,Hospitalization causes and outcomes in HIV patients in the late antiretroviral era in Colombia,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0186-3
104,HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0185-4
105,Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment Program,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0184-5
106,The role of the glycosyl moiety of myricetin derivatives in anti-HIV-1 activity in vitro,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0183-6
107,Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0182-7
108,Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0179-2
109,HIV vaccine research in Canada,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0181-8
110,HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0175-6
111,A novel HIV vaccine targeting the protease cleavage sites,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0174-7
112,Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0178-3
113,The biology of how circumcision reduces HIV susceptibility: broader implications for the prevention field,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0167-6
114,Potential contribution of gut microbiota and systemic inflammation on HIV vaccine effectiveness and vaccine design,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0164-9
115,Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0176-5
116,Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0166-7
117,Eradication of HIV-1 latent reservoirs through therapeutic vaccination,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0177-4
118,Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0173-8
119,Development of targeted adjuvants for HIV-1 vaccines,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0165-8
120,Unlocking HIV-1 Env: implications for antibody attack,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0168-5
121,Modulation of the strength and character of HIV-specific CD8+ T cell responses with heteroclitic peptides,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0170-y
122,"RNA flow cytometric FISH for investigations into HIV immunology, vaccination and cure strategies",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0171-x
123,Role of sex hormones and the vaginal microbiome in susceptibility and mucosal immunity to HIV-1 in the female genital tract,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0169-4
124,Natural killer (NK) cell receptor-HLA ligand genotype combinations associated with protection from HIV infection: investigation of how protective genotypes influence anti HIV NK cell functions,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0172-9
125,Factors affecting affect cardiovascular health in Indonesian HIV patients beginning ART,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0180-9
126,A frailty index predicts post-liver transplant morbidity and mortality in HIV-positive patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0163-x
127,High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0161-z
128,Bone mineral density in people living with HIV: a narrative review of the literature,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0162-y
129,Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM),http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0160-0
130,Transition into adult care: factors associated with level of preparedness among adolescents living with HIV in Cambodia,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0159-6
131,The therapeutic landscape of HIV-1 via genome editing,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0157-8
132,The dynamic changes of interferon lambdas related genes and proteins in JAK/STAT pathway in both acute and chronic HIV-1 infected patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0158-7
133,"Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0156-9
134,Erratum to: Hospital days attributable to immune reconstitution inflammatory syndrome in persons living with HIV before and after the 2012 DHHS HIV guidelines,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0155-x
135,The developmental effects of HIV and alcohol: a comparison of gestational outcomes among babies from South African communities with high prevalence of HIV and alcohol use,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0153-z
136,Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0151-1
137,"COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0154-y
138,Hospital days attributable to immune reconstitution inflammatory syndrome in persons living with HIV before and after the 2012 DHHS HIV guidelines,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0152-0
139,Molecular diagnosis of central nervous system opportunistic infections and mortality in HIV-infected adults in Central China,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0150-2
140,"Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0149-8
141,What influences quality of life in older people living with HIV?,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0148-9
142,Validity assessment of the PROMIS fatigue domain among people living with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0146-y
143,Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0138-y
144,Antiretroviral therapy supply chain quality control and assurance in improving people living with HIV therapeutic outcomes in Cameroon,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0147-x
145,"CLINICAL outcomes and loss to follow-up among people living with HIV participating in the NAMWEZA intervention in Dar es Salaam, Tanzania: a prospective cohort study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0145-z
146,Barriers to uptake of early infant HIV testing in Zambia: the role of intimate partner violence and HIV status disclosure within couples,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0142-2
147,Determinants to antiretroviral treatment non-adherence among adult HIV/AIDS patients in northern Ethiopia,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0143-1
148,Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0144-0
149,"Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region)",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0141-3
150,Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0140-4
151,Possible misdiagnosis of HIV associated lymphoma as tuberculosis among patients attending Uganda Cancer Institute,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0139-x
152,Characterization of occult hepatitis B virus infection among HIV positive patients in Cameroon,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0136-0
153,"HIV care in Yangon, Myanmar; successes, challenges
and implications for policy",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0137-z
154,Distribution and fate of HIV-1 unintegrated DNA species: a comprehensive update,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0127-6
155,Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0129-4
156,H1N1 influenza vaccination in HIV-infected women on effective antiretroviral treatment did not induce measurable antigen-driven proliferation of the HIV-1 proviral reservoir,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0135-1
157,Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0134-2
158,Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0132-4
159,"HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0133-3
160,Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: a systematic review,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-017-0131-5
161,Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0130-y
162,Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0128-5
163,Integrated therapy for HIV and cryptococcosis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0126-7
164,Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0125-8
165,Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0121-z
166,HIV sero-discordance among married HIV patients initiating anti-retroviral therapy in northern Vietnam,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0124-9
167,"Trends in clinical characteristics and outcomes of Pre-ART care at a large HIV clinic in Nairobi, Kenya: a retrospective cohort study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0122-y
168,Re-focusing HIV prevention messages: a qualitative study in rural Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0123-x
169,Quasi-Poisson versus negative binomial regression models in identifying factors affecting initial CD4 cell count change due to antiretroviral therapy administered to HIV-positive adults in North–West Ethiopia (Amhara region),http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0119-6
170,"The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0120-0
171,Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0118-7
172,Targeting vulnerable populations: a synthetic review on alcohol use and risky sexual behaviour among migrant populations,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0117-8
173,Nutritional status and its effect on treatment outcome among HIV infected clients receiving HAART in Ethiopia: a cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0116-9
174,Stem cell transplantation in strategies for curing HIV/AIDS,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0114-y
175,"Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0115-x
176,Early infant diagnosis of HIV infection using DNA-PCR at a referral center: an 8 years retrospective analysis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0112-0
177,The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0113-z
178,Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0111-1
179,Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0108-9
180,Risk factors for unstructured treatment interruptions and association with survival in low to middle income countries,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0109-8
181,Determinants of time to antiretroviral treatment initiation and subsequent mortality on treatment in a cohort in rural northern Malawi,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0110-2
182,Prevalence of HIV and hepatitis B coinfection in Ghana: a systematic review and meta-analysis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0107-x
183,Integrated therapy for HIV and tuberculosis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0106-y
184,What happens to cardiovascular system behind the undetectable level of HIV viremia?,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0105-z
185,Evolution of changes in cognitive function after the initiation of antiretroviral therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0104-0
186,"Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0103-1
187,Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0102-2
188,Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0101-3
189,Factors associated with HIV viral load “blips” and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case–control study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0100-4
190,"The role of NK cells in HIV-1 protection: autologous, allogeneic or both?",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0099-6
191,"Predictors of perceived male partner concurrency among women at risk for HIV and STI acquisition in Durban, South Africa",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0098-7
192,Reviewer acknowledgement,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0097-8
193,"High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0094-y
194,Acceptability and use of ready-to-use supplementary food compared to corn–soy blend as a targeted ration in an HIV program in rural Haiti: a qualitative study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0096-9
195,"Rate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow up study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0095-x
196,Assessing the sensitivity and specificity of First Response HIV-1-2 test kit with whole blood and serum samples: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0092-0
197,Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0091-1
198,The antiviral compound BIT225 inhibits HIV-1 replication in myeloid dendritic cells,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0093-z
199,"Sero-prevalence of HBV and associated risk factors among HIV positive individuals attending ART clinic at Mekelle hospital, Tigray, Northern Ethiopia",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0090-2
200,Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-016-0089-8
201,The adult prevalence of HIV in Zambia: results from a population based mobile testing survey conducted in 2013–2014,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0088-1
202,"HIV-1 genetic diversity and its distribution characteristics among newly diagnosed HIV-1 individuals in Hebei province, China",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0087-2
203,Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0084-5
204,Spectrum of false positivity for the fourth generation human immunodeficiency virus diagnostic tests,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0086-3
205,Resolved lower limb muscle tone abnormalities in children with HIV encephalopathy receiving standard antiretroviral therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0085-4
206,Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: a cross sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0083-6
207,HIV patients stable on ART retain evidence of a high CMV load but changes to Natural Killer cell phenotypes reflect both HIV and CMV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0080-9
208,"Determinants of late presentation to HIV/AIDS care in Southern Tigray Zone, Northern Ethiopia: an institution based case–control study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0079-2
209,Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0081-8
210,Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0082-7
211,Community-based ART distribution system can effectively facilitate long-term program retention and low-rates of death and virologic failure in rural Uganda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0077-4
212,"HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0078-3
213,Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0076-5
214,Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0066-7
215,Development of cryptococcal immune reconstitution inflammatory syndrome 41 months after the initiation of antiretroviral therapy in an AIDS patient,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0075-6
216,"Rates and risk factors associated with the progression of HIV to AIDS among HIV patients from Zhejiang, China between 2008 and 2012",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0074-7
217,Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0072-9
218,Sensory neuropathy and metabolic risk factors in human immune deficiency virus infected South Africans receiving protease inhibitors,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0073-8
219,Enhanced oxidative stress by alcohol use in HIV+ patients: possible involvement of cytochrome P450 2E1 and antioxidant enzymes,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0071-x
220,Low prevalence of human leukocyte antigen-B*5701 in HIV-1-infected Chinese subjects: a prospective epidemiological investigation,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0064-9
221,HIV-1 protease inhibitor drug resistance in Kenyan antiretroviral treatment-naive and -experienced injection drug users and non-drug users,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0070-y
222,Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0069-4
223,Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0067-6
224,"Changes in blood pressure, glucose levels, insulin secretion and anthropometry after long term exposure to antiretroviral therapy in South African women",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0065-8
225,The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0063-x
226,"Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010–2011",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0062-y
227,Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0061-z
228,"Trends in prevalence of diarrhoea, Kaposi’s sarcoma, bacterial pneumonia, malaria and geohelminths among HIV positive individuals in Uganda",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0060-0
229,"Disease progression of HIV-1 infection in symptomatic and asymptomatic seroconverters in Osaka, Japan: a retrospective observational study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0059-6
230,Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0054-y
231,Factors related to NT-proBNP levels in HIV patients aged over 40 years,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0058-7
232,The difficult management of disseminated Sporothrix brasiliensis in a patient with advanced AIDS,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0051-1
233,Partner notification in the context of HIV: an interest-analysis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0057-8
234,"Nutritional status and its association with quality of life among people living with HIV attending public anti-retroviral therapy sites of Kathmandu Valley, Nepal",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0056-9
235,Osteonecrosis of the jaw in an AIDS patient: a case report,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0049-8
236,"Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0053-z
237,Determination of HIV-1 coreceptor tropism using proviral DNA in women before and after viral suppression,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0055-x
238,Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0052-0
239,The impact of HIV/AIDS on compliance with antidepressant treatment in major depressive disorder: A prospective study in a South African private healthcare cohort,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0050-2
240,Strong correlation between protein reagent strip and protein-to-creatinine ratio for detection of renal dysfunction in HIV-infected patients: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0047-x
241,Influence of quinacrine and chloroquine on the in vitro 3′-azido-3′-deoxythymidine antiretroviral effect,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0048-9
242,An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0044-0
243,"HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, Indonesia",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0046-y
244,Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0045-z
245,Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007–2010) – TASER-S,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-015-0043-1
246,HIV Encephalopathy: pediatric case series description and insights from the clinic coalface,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-014-0042-7
247,Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-014-0041-8
248,Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/s12981-014-0040-9
249,"Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-39
250,Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-38
251,Successful use of extracorporeal membrane oxygenation in a human immunodeficiency virus infected patient with severe acute respiratory distress syndrome,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-37
252,The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-36
253,A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-35
254,Acute tubular nephropathy in a patient with acute HIV infection: review of the literature,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-34
255,Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-33
256,Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-32
257,"High prevalence and incidence of sexually transmitted infections among women living in Kwazulu-Natal, South Africa",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-31
258,Greater frequency of CD5-negative CD8+ T cells against human immunodeficiency virus type 1 than other viruses is consistent with adaptation to antigenic variation,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-30
259,"Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-29
260,Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-28
261,Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4+ T cell recovery after the initiation of antiretroviral therapy for HIV disease,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-27
262,The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-26
263,Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-25
264,Influence of providers and nurses on completion of non-targeted HIV screening in an urgent care setting,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-24
265,Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-23
266,Compare mDCs and pDCs between two distinct patients groups in acute HIV-1 infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-22
267,HCV RNA viral load is independent from CD4 cell count and plasma HIV RNA viral load in immunocompetent HIV-HCV co-infected patients: a 3-years follow-up study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-21
268,Cerebral microsporidiosis manifesting as progressive multifocal leukoencephalopathy in an HIV-infected individual - a case report,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-20
269,"The prevalence of transmitted HIV drug resistance among MSM in Anhui province, China",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-19
270,Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-18
271,The effects of opioids on HIV reactivation in latently-infected T-lymphoblasts,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-17
272,German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-16
273,"Diagnoses, prevalence, and state-based federal spending for HIV prevention and treatment in the United States, 2006–2009",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-15
274,A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-14
275,Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND),http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-13
276,Prophylactic and therapeutic effect of AZT/3TC in RT-SHIV infected Chinese-origin rhesus macaques,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-12
277,HIV post exposure prophylaxis induced bicytopenia: a case report,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-11
278,Reviewer acknowledgement,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-8
279,Race/ethnicity and HAART initiation in a military HIV infected cohort,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-10
280,HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-9
281,Association between lymphocyte and monocyte subsets and cognition in children with HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-7
282,Morning free and total testosterone in HIV-infected men: implications for the assessment of hypogonadism,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-6
283,"HIV serostatus disclosure among people living with HIV/AIDS in Mwanza, Tanzania",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-5
284,Brain biopsy in AIDS patients: diagnostic yield and treatment applications,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-4
285,"Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-3
286,Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-2
287,The D-amino acid peptide D3 reduces amyloid fibril boosted HIV-1 infectivity,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-11-1
288,Differential inflammasome expression and IL-1β secretion in monocyte-derived dendritic cells differentiated with IL-4 or IFN-α,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-35
289,Effects of highly active antiretroviral therapy and its adherence on herpes zoster incidence: a longitudinal cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-34
290,Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-33
291,Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-32
292,Putting an ‘End’ to HIV mRNAs: capping and polyadenylation as potential therapeutic targets,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-31
293,Women and HIV in Sub-Saharan Africa,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-30
294,Serious Non-AIDS events: Immunopathogenesis and interventional strategies,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-29
295,World AIDS Day Commemoration,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-28
296,Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-27
297,Coregulation of HIV-1 dependency factors in individuals heterozygous to the CCR5-delta32 deletion,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-26
298,Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-25
299,"Population specific reference ranges of CD3, CD4 and CD8 lymphocyte subsets among healthy Kenyans",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-24
300,Seroprevalence of Schistosomiasis and Strongyloides infection in HIV-infected patients from endemic areas attending a European infectious diseases clinic,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-23
301,Susac’s syndrome as HIV-associated immune reconstitution inflammatory syndrome,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-22
302,"Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-21
303,Collective patient behaviours derailing ART roll-out in KwaZulu-Natal: perspectives of health care providers,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-20
304,Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: a prospective cohort analysis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-19
305,"Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-18
306,"Sexual risk behaviour, marriage and ART: a study of HIV-positive people in Papua New Guinea",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-17
307,"Tuberculous meningitis: presentation, diagnosis and outcome in hiv-infected patients at the douala general hospital, cameroon: a cross sectional study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-16
308,Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-15
309,The utility of self-emulsifying oil formulation to improve the poor solubility of the anti HIV drug CSIC,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-14
310,Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-13
311,"Self-care practices and experiences of people living with HIV not receiving antiretroviral therapy in an urban community of Lusaka, Zambia: implications for HIV treatment programmes",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-12
312,A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-11
313,In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-10
314,Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-9
315,HIV testing practices among New England college health centers,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-8
316,Reviewer acknowledgment,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-6
317,"Prevalence of intestinal parasites and associated risk factors among HIV/AIDS patients with pre-ART and on-ART attending dessie hospital ART clinic, Northeast Ethiopia",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-7
318,"NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-5
319,Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-4
320,Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-3
321,"Erratum to: Total Lymphocyte Count as surrogate marker for CD4 Cell Count in HIV-Infected Individuals in Gondar University Hospital, Northwest Ethiopia",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-2
322,A new system for parallel drug screening against multiple-resistant HIV mutants based on lentiviral self-inactivating (SIN) vectors and multi-colour analyses,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-10-1
323,"HIV serostatus disclosure is not associated with safer sexual behavior among HIV-positive men who have sex with men (MSM) and their partners at risk for infection in Bangkok, Thailand",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-38
324,Trends and determining factors associated with adherence to antiretroviral therapy (ART) in Cameroon: a systematic review and analysis of the CAMPS trial,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-37
325,Anti-infective treatment in HIV-infected patients during perioperative period,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-36
326,HIV-associated sensory neuropathy in HIV-1 infected patients at the Douala General Hospital in Cameroon: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-35
327,Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-34
328,Prevalence of and risk factors for MRSA colonization in HIV-positive outpatients in Singapore,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-33
329,Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-32
330,Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-31
331,ART adherence changes among patients in community substance use treatment: a preliminary analysis from MACH14,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-30
332,"Metabolic syndrome and population attributable risk among HIV/AIDS patients: comparison between NCEP-ATPIII, IDF and AHA/NHLBI definitions",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-29
333,"Mortality and loss to programme before antiretroviral therapy among HIV-infected children eligible for treatment in The Gambia, West Africa",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-28
334,Should highly active antiretroviral therapy be prescribed in critically ill HIV-infected patients during the ICU stay? A retrospective cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-27
335,"Utility of the point of care CD4 analyzer, PIMA, to enumerate CD4 counts in the field settings in India",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-26
336,A study of the prevalence and risk factors leading to HIV infection among a sample of street children and youth of Kathmandu,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-25
337,Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-24
338,Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-23
339,Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-22
340,"Total Lymphocyte Count as surrogate marker for CD4 Cell Count in HIV-Infected Individuals in Gondar University Hospital, Northwest Ethiopia",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-21
341,High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-20
342,Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-19
343,Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-18
344,Tuberculosis associated immune reconstitution inflammatory syndrome in patients infected with HIV: meningitis a potentially life threatening manifestation,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-17
345,Dual role of autophagy in HIV-1 replication and pathogenesis,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-16
346,Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-15
347,Is the Sexual Behaviour of HIV Patients on Antiretroviral therapy safe or risky in Sub-Saharan Africa? Meta-Analysis and Meta-Regression,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-14
348,"Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-13
349,A home-based approach to managing multi-drug resistant tuberculosis in Uganda: a case report,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-12
350,The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-11
351,Spontaneous virologic suppression in HIV controllers is independent of delayed-type hypersensitivity test responsiveness,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-10
352,"Sexual behavior of HIV-positive adults not accessing HIV treatment in Mombasa, Kenya: Defining their prevention needs",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-9
353,Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-8
354,"Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-7
355,Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-6
356,HIV-1 Subtype distribution in morocco based on national sentinel surveillance data 2004-2005,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-5
357,"Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-4
358,Combination antiretroviral therapy and chronic HIV infection affect serum retinoid concentrations: longitudinal and cross-sectional assessments,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-3
359,Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-2
360,Use of dietary supplements among people living with HIV/AIDS is associated with vulnerability to medical misinformation on the internet,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-9-1
361,Gender variation in self-reported likelihood of HIV infection in comparison with HIV test results in rural and urban Nigeria,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-44
362,"Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-43
363,"Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-42
364,The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-41
365,Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-40
366,"Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-39
367,"Reverse transcriptase drug resistance mutations in HIV-1 subtype C infected patients on ART in Karonga District, Malawi",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-38
368,HIV-free survival and morbidity among formula-fed infants in a prevention of mother-to-child transmission of HIV program in rural Haiti,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-37
369,HIV-1 transgene expression in rats induces differential expression of tumor necrosis factor alpha and zinc transporters in the liver and the lung,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-36
370,Establishment of reference CD4+ T cell values for adult Indian population,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-35
371,Immune reconstitution syndrome presenting as probable AIDS-related lymphoma: a case report,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-34
372,First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-33
373,Developing quality indicators for the care of HIV-infected pregnant women in the Dutch Caribbean,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-32
374,Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-31
375,Chronic alcohol ingestion exacerbates skeletal muscle myopathy in HIV-1 transgenic rats,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-30
376,Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-29
377,Addressing the fear and consequences of stigmatization - a necessary step towards making HAART accessible to women in Tanzania: a qualitative study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-28
378,"Preformulation and stability in biological fluids of the retrocyclin RC-101, a potential anti-HIV topical microbicide",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-27
379,HIV-1 mutational pathways under multidrug therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-26
380,Characteristics of HIV-infected women and factors associated with HCV seropositivity in the Republic of Georgia,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-25
381,"Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-24
382,"Opportunistic illnesses in Brazilian children with AIDS: results from two national cohort studies, 1983-2007",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-23
383,Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-22
384,Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-21
385,T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-20
386,Contraception in HIV-positive female adolescents,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-19
387,Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-18
388,Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-17
389,Possible transmission of HIV Infection due to human bite,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-16
390,Characteristics of CD8+ T cell subsets in Chinese patients with chronic HIV infection during initial ART,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-15
391,Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-14
392,"Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-13
393,Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-12
394,Trends and determinants of Comprehensive HIV and AIDS knowledge among urban young women in Kenya,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-11
395,Health system weaknesses constrain access to PMTCT and maternal HIV services in South Africa: a qualitative enquiry,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-10
396,Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-9
397,Factors associated with late presentation to HIV/AIDS care in South Wollo ZoneEthiopia: a case-control study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-8
398,The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-7
399,Control of viral replication after cessation of HAART,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-6
400,A comparison of the MOS-HIV and SF-12v2 for measuring health-related quality of life of men and women living with HIV/AIDS,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-5
401,The impact of the National HIV Health Care Worker Hotline on patient care in South Africa,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-4
402,Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-3
403,Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-2
404,Multiple shRNA combinations for near-complete coverage of all HIV-1 strains,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-8-1
405,"HIV, appendectomy and postoperative complications at a reference hospital in Northwest Tanzania: cross-sectional study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-47
406,"Immune restoration disease and changes in CD4+ T-cell count in HIV- infected patients during highly active antiretroviral therapy at Zewditu memorial hospital, Addis Ababa, Ethiopia",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-46
407,CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-45
408,Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-44
409,HIVBrainSeqDB: a database of annotated HIV envelope sequences from brain and other anatomical sites,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-43
410,Varied sensitivity to therapy of HIV-1 strains in CD4+ lymphocyte sub-populations upon ART initiation,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-42
411,Structure of HIV-1 quasi-species as early indicator for switches of co-receptor tropism,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-41
412,Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-40
413,Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-39
414,A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-38
415,Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-37
416,Multi-analyte profiling of ten cytokines in South African HIV-infected patients with Immune Reconstitution Inflammatory Syndrome (IRIS),http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-36
417,Mobile learning for HIV/AIDS healthcare worker training in resource-limited settings,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-35
418,Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan women,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-34
419,"Food assistance is associated with improved body mass index, food security and attendance at clinic in an HIV program in central Haiti: a prospective observational cohort study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-33
420,"Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-32
421,Specific eradication of HIV-1 from infected cultured cells,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-31
422,"Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-30
423,"Utility of clinical assessment, imaging, and cryptococcal antigen titer to predict AIDS-related complicated forms of cryptococcal meningitis",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-29
424,Genetic and functional analysis of HIV-1 Rev Responsive Element (RRE) sequences from North-India,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-28
425,Autoprocessing of human immunodeficiency virus type 1 protease miniprecursor fusions in mammalian cells,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-27
426,Alkylating HIV-1 Nef - a potential way of HIV intervention,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-26
427,Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-25
428,Co-receptor tropism prediction among 1045 Indian HIV-1 subtype C sequences: Therapeutic implications for India,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-24
429,"Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-23
430,Safety and anti-HIV assessments of natural vaginal cleansing products in an established topical microbicides in vitro testing algorithm,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-22
431,The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-21
432,Nef-specific CD45RA+ CD8+ T cells secreting MIP-1β but not IFN-γ are associated with nonprogressive HIV-1 infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-20
433,The impact of Highly Active Antiretroviral Therapy (HAART) on the clinical features of HIV - related oral lesions in Nigeria,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-19
434,Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-18
435,"An exploratory survey of money boys and HIV transmission risk in Jilin Province, PR China",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-17
436,Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-16
437,Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-15
438,Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-14
439,Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-13
440,Recent key advances in human immunodeficiency virus medicine and implications for China,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-12
441,Elevated risks of death for diabetes mellitus and cardiovascular diseases in Italian AIDS cases,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-11
442,"Experiences in conducting multiple community-based HIV prevention trials among women in KwaZulu-Natal, South Africa",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-10
443,Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-9
444,Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-8
445,Inhibition of human immunodeficiency virus type-1 by cdk inhibitors,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-7
446,"Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-6
447,"Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-5
448,HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-4
449,Further benefits by early start of HIV treatment in low income countries: Survival estimates of early versus deferred antiretroviral therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-3
450,Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross - sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-2
451,Another look at Emergency Department HIV screening in practice: no need to revise expectations,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-7-1
452,Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-30
453,"Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-29
454,"Genetic analysis of HIV-1 Circulating Recombinant Form 02_AG, B and C subtype-specific envelope sequences from Northern India and their predicted co-receptor usage",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-28
455,Comparative analysis of cell culture and prediction algorithms for phenotyping of genetically diverse HIV-1 strains from Cameroon,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-27
456,Treatment of hypertriglyceridemia and HIV: fenofibrate-induced changes in the expression of chemokine genes in circulating leukocytes,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-26
457,Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-25
458,Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-24
459,"RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-23
460,HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-22
461,"Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: a prospective study at Yaounde Central Hospital, Cameroon",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-21
462,Detection of HIV-1 RNA/DNA and CD4 mRNA in feces and urine from chronic HIV-1 infected subjects with and without anti-retroviral therapy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-20
463,"Protease inhibitor-induced nausea and vomiting is attenuated by a peripherally acting, opioid-receptor antagonist in a rat model",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-19
464,"Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept®, Roche): overview",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-18
465,"The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-17
466,Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS),http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-16
467,Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-15
468,"Comparison of metal-dependent catalysis by HIV-1 and ASV integrase proteins using a new and rapid, moderate throughput assay for joining activity in solution",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-14
469,Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-13
470,"Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-12
471,Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-11
472,Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-10
473,An alternative methodology for the prediction of adherence to anti HIV treatment,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-9
474,Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: A substudy of the Multicenter AIDS Cohort Study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-8
475,"Adherence to anti-retroviral therapy among HIV patients in Bangalore, India",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-7
476,Ankle-brachial index in HIV infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-6
477,Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-5
478,Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-4
479,"A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-3
480,Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives?,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-2
481,HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-6-1
482,"Relationship between Total Lymphocyte count (TLC) and CD4 count among peoples living with HIV, Southern Ethiopia: a retrospective evaluation",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-26
483,Traditional Indian medicine and homeopathy for HIV/AIDS: a review of the literature,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-25
484,A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-24
485,Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on Antiretroviral Therapy (ART) in sub-Saharan Africa: Frequency and clinical significance,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-23
486,The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-22
487,"Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-21
488,Predictive validity of a brief antiretroviral adherence index: Retrospective cohort analysis under conditions of repetitive administration,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-20
489,Microbicides 2008 conference: From discovery to advocacy,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-19
490,HIV-2 diagnosis and quantification in high-risk patients,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-18
491,The feasibility of preventing mother-to-child transmission of HIV using peer counselors in Zimbabwe,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-17
492,Stable gene transfer of CCR5 and CXCR4 siRNAs by sleeping beauty transposon system to confer HIV-1 resistance,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-16
493,The Iranian female high school students' attitude towards people with HIV/AIDS: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-15
494,The impact of HIV-associated lipodystrophy on healthcare utilization and costs,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-14
495,"Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naïve HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-13
496,"Two specific drugs, BMS-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-12
497,Substitution of the Rev-response element in an HIV-1-based gene delivery system with that of SIVmac239 allows efficient delivery of Rev M10 into T-lymphocytes,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-11
498,"Pre-clinical development as microbicide of zinc tetra-ascorbo-camphorate, a novel terpenoid derivative: Potent in vitro inhibitory activity against both R5- and X4-tropic HIV-1 strains without significant in vivo mucosal toxicity",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-10
499,Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-9
500,Effect of HIV-1-related protein expression on cardiac and skeletal muscles from transgenic rats,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-8
501,Barriers to access prevention of mother-to-child transmission for HIV positive women in a well-resourced setting in Vietnam,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-7
502,Determinants of late disease-stage presentation at diagnosis of HIV infection in Venezuela: A case-case comparison,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-6
503,"Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-5
504,"Use of WHO clinical stage for assessing patient eligibility to antiretroviral therapy in a routine health service setting in Jinja, Uganda",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-4
505,Summary of presentations at the NIH/NIAID New Humanized Rodent Models 2007 Workshop,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-3
506,The prognostic significance of facial lymphoedema in HIV-seropositive subjects with Kaposi sarcoma,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-2
507,Human embryonic stem cell (hES) derived dendritic cells are functionally normal and are susceptible to HIV-1 infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-5-1
508,Immune reconstitution inflammatory syndrome in association with HIV/AIDS and tuberculosis: Views over hidden possibilities,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-29
509,Provider-initiated HIV testing in rural Haiti: low rate of missed opportunities for diagnosis of HIV in a primary care clinic,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-28
510,"Missed opportunities for participation in prevention of mother to child transmission programmes: Simplicity of nevirapine does not necessarily lead to optimal uptake, a qualitative study",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-27
511,Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-26
512,Bacterial vaginosis and human immunodeficiency virus infection,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-25
513,Instability of retroviral vectors with HIV-1-specific RT aptamers due to cryptic splice sites in the U6 promoter,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-24
514,Trends in HIV-1 prevalence and risk behaviours over 15 years in a rural population in Kilimanjaro region of Tanzania,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-23
515,Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-22
516,Immune Restoration Syndrome with disseminated Penicillium marneffei and Cytomegalovirus co-infections in an AIDS patient,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-21
517,"Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-20
518,Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-19
519,Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD),http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-18
520,Use of a population-based survey to determine incidence of AIDS-defining opportunistic illnesses among HIV-positive persons receiving medical care in the United States,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-17
521,"HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-16
522,Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus – 1 (HIV-1) infected pediatric patients: a cross-sectional study,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-15
523,HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-14
524,BK virus associated meningoencephalitis in an AIDS patient treated with HAART,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-13
525,"Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-12
526,Predictors of disease progression in HIV infection: a review,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-11
527,Media and education play a tremendous role in mounting AIDS awareness among married couples in Bangladesh,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-10
528,Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-9
529,Gender-specific effects of HIV protease inhibitors on body mass in mice,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-8
530,"Perceptions of vaginal microbicides as an HIV prevention method among health care providers in KwaZulu-Natal, South Africa",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-7
531,"Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-6
532,"Rodlach Alexander: Witches, Westerners, and HIV: AIDS and Cultures of Blame in Africa Walnut Creek, California: Left Coast Press; 2006. 247 pages, ISBN 1-59874-033-4 (hardback) and 1-59874-034-2 (paperback)",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-5
533,"Trends in the HIV related hospital admissions in the HAART era in Barbados, 2004–2006",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-4
534,Retroviral rebound syndrome after treatment discontinuation in a 15 year old girl with HIV attracted through mother-to-child transmission: case report,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-3
535,Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338),http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-2
536,"Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-4-1
537,"Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-30
538,Post-exposure prophylaxis for SIV revisited: Animal model for HIV prevention,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-29
539,HLA-G DNA sequence variants and risk of perinatal HIV-1 transmission,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-28
540,"HIV among pregnant women in Moshi Tanzania: the role of sexual behavior, male partner characteristics and sexually transmitted infections",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-27
541,Comparison of capillary based microflurometric assay for CD4+ T cell count estimation with dual platform Flow cytometry,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-26
542,Microbicides 2006 conference,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-25
543,"Niekerk Anton A, Kopelman Loretta M: Ethics and AIDS in Africa: The Challenge to our Thinking Walnut Creek, California: Left Coast Press; 2005. 222 pages, ISBN 1-59874-070-9",http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-24
544,Prevention for those who have freedom of choice – or among the choice-disabled: confronting equity in the AIDS epidemic,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-23
545,Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-22
546,Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-21
547,Predicting AIDS-related events using CD4 percentage or CD4 absolute counts,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-20
548,The effect of different combination therapies on oxidative stress markers in HIV infected patients in cameroon,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-19
549,IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-18
550,Body image in women with HIV: a cross-sectional evaluation,http://aidsrestherapy.biomedcentral.com/track/pdf/10.1186/1742-6405-3-17
